Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.42 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056321 | 1.00 | JAK2 (0.42) | JAK2BCL6SOS1EGLN2MAP4K4 | |
| SCHEMBL29635166 | 0.80 | ACACB (0.41) | FGFR4 | |
| SCHEMBL19866866 | 0.80 | ACACB (0.41) | FGFR4 | |
| SCHEMBL29596935 | 0.80 | ACACB (0.41) | FGFR4 | |
| SCHEMBL19630300 | 0.80 | ACACB (0.41) | FGFR4 | |
| SCHEMBL17796326 | 0.79 | MAP4K4 (0.43) | JAK2MAP4K4HRH4HRH3JAK3 | |
| SCHEMBL17796330 | 0.79 | MAP4K4 (0.43) | JAK2MAP4K4HRH4HRH3JAK3 | |
| SCHEMBL17796327 | 0.79 | MAP4K4 (0.43) | JAK2MAP4K4HRH4HRH3JAK3 | |
| SCHEMBL1748798 | 0.78 | GAA (0.48) | JAK2BCL6SOS1EGLN2MAP4K4 | |
| SCHEMBL22023340 | 0.77 | PIK3CA (0.42) | MAP4K4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-21 | — | — | US | disclosed |
| CN-109563091-B | FGFR4 inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220024913-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024913-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| EP-3498707-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024913-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | JAK2 258/4885BCL6 2389/4885SOS1 1598/4885 |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | JAK2 258/4885BCL6 2389/4885SOS1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.